Guillaume Bouguen
Overview
Explore the profile of Guillaume Bouguen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
139
Citations
1666
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Richard N, Amiot A, Seksik P, Altwegg R, Laharie D, Vuitton L, et al.
Aliment Pharmacol Ther
. 2025 Mar;
PMID: 40038887
Background: Real-world effectiveness and safety of upadacitinib in patients with Crohn's disease (CD) remain unclear. Aims: This study aimed to evaluate the effectiveness and safety of upadacitinib in a real-world...
2.
Buffet-Bataillon S, Durao G, Le Huerou-Luron I, Rue O, Le Cunff Y, Cattoir V, et al.
Front Cell Infect Microbiol
. 2025 Feb;
15:1540352.
PMID: 40007605
Introduction: Crohn's disease (CD) results from alterations in the gut microbiota and the immune system. However, the exact metabolic dysfunctions of the gut microbiota during CD are still unclear. Here,...
3.
Franck B, Tron C, Verdier M, Bellissant E, Peaucelle A, Roblin X, et al.
Ther Drug Monit
. 2024 Dec;
47(2):265-273.
PMID: 39621838
Background: Therapeutic drug monitoring of infliximab is commonly performed based on trough concentration. However, doses and dosing intervals may be adapted to patient outcomes, and this trough concentration target may...
4.
Amiot A, Seksik P, Meyer A, Stefanescu C, Wils P, Altwegg R, et al.
Gut
. 2024 Nov;
74(2):197-205.
PMID: 39586616
Background: It is unknown which maintenance therapy is the most effective option for patients admitted for an acute severe ulcerative colitis (ASUC) episode responding to intravenous steroids. Methods: We conducted...
5.
Bouguen G, Gossec L, Abitbol V, Senbel E, Bonnaud G, Roblin X, et al.
BioDrugs
. 2024 Sep;
38(6):867-878.
PMID: 39322802
Background And Objectives: Biosimilars are cost-effective alternatives to reference products for patients with inflammatory bowel diseases (IBD) and chronic inflammatory rheumatic diseases (CIRD), but patient beliefs can affect adherence to...
6.
Buisson A, Junda J, Vignette J, Lecoq E, Bouguen G, Goutorbe F, et al.
Clin Gastroenterol Hepatol
. 2024 Jun;
22(11):2271-2279.e11.
PMID: 38908734
Background & Aims: Because transmural healing (TH) could be the best therapeutic target in Crohn's disease (CD), we aimed to build and validate a score to assess TH and transmural...
7.
Fumery M, Serrero M, Bouguen G, Amiot A, Altwegg R, Nachury M, et al.
J Crohns Colitis
. 2024 May;
18(10):1615-1621.
PMID: 38742654
Background: Both vedolizumab and ustekinumab can be considered for the treatment of ulcerative colitis [UC], but head-to-head trials are lacking. Aim: We aimed to compare the effectiveness of vedolizumab and...
8.
Queneherve L, Trang-Poisson C, Fantou A, Flamant M, Durand T, Bouguen G, et al.
PLoS One
. 2024 Apr;
19(4):e0298313.
PMID: 38564601
Aims: In patients with ulcerative colitis (UC), no biomarker is available to help the physician to choose the most suitable biotherapy. The primary objective of this pilot study was to...
9.
Fathallah N, Siproudhis L, Akaffou M, Haouari M, Landemaine A, Pommaret E, et al.
Colorectal Dis
. 2023 Oct;
25(11):2170-2176.
PMID: 37849054
Aim: The aim of this study was to evaluate the real-life clinical and radiological efficacy of darvadstrocel injection into complex perianal fistulas in Crohn's disease. Secondary endpoints were to assess...
10.
Uzzan M, Nachury M, Nuzzo A, Amiot A, Caron B, Benezech A, et al.
J Crohns Colitis
. 2023 Oct;
18(3):424-430.
PMID: 37796025
Background: Although ulcerative proctitis [UP] can dramatically impair quality of life, treatment efficacy has been poorly investigated in UP as it was historically excluded from phase 2/3 randomised controlled trials...